Healthcare / Medical Care FacilitiesJakarta
$83.00
-1.00 (-1.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-6.8B · quality 31.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$280.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-2.3%
↓Gross Margin
21.5%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.0%
FCF CAGR
—
FCF margin
-2.0%
FCF / Net income
0.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $338.91B · net income $-21.82B · FCF $-6.81B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $338.91B | $338.91B | $299.36B | $265.34B | $261.93B |
| Net Income | $-21.82B | $-21.82B | $-18.41B | $-2.75B | $21.59B |
| EBITDA | $-19.28B | $-19.28B | $-17.09B | $-585.8M | $33.52B |
| EPS | -6.43 | -6.43 | -5.42 | -0.81 | 6.37 |
| Gross Margin | 21.5% | 21.5% | 24.8% | 28.4% | 36.8% |
| Operating Margin | -7.0% | -7.0% | -7.1% | -1.7% | 9.1% |
| Net Margin | -6.4% | -6.4% | -6.1% | -1.0% | 8.2% |
| Balance Sheet | |||||
| Current Ratio | 2.17 | 2.17 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.81B | $-6.81B | $-5.78B | $-39.98B | $-196.45B |
| Returns | |||||
| ROE | -2.3% | -2.3% | -1.9% | -0.3% | 2.2% |
| Valuation | |||||
| P/E | — | — | — | — | 27.79 |
| EV/EBITDA | — | — | — | — | 15.97 |
| P/B | 0.30 | 0.30 | 0.20 | 0.30 | 0.61 |
| Growth & Yield | |||||
| Revenue Growth | 13.2% | 13.2% | 12.8% | 1.3% | — |
| EPS Growth | -18.6% | -18.6% | -569.1% | -112.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+38.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-5.42 → -6.43
Residual
+38.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.